[Medical treatment of venous priapism apropos of 46 cases: puncture, pharmacologic detumescence or penile cooling?].
OBJECTIVE
To analyse the efficacy of three nonspecific medical approaches to the first-line treatment of priapism : a) intracavernous injection (ICI) of alpha-adrenergic agonists, b) cavernous puncture, c) penile cutaneous cooling.


METHODS
46 cases of venous priapism, due to various aetiologies, were initially treated by ICI of alpha-adrenergic agonists (23 cases), puncture (14 cases) or cooling (9 cases). These 3 methods were combined only in the case of failure and not uniformly, based on our experience. The results were analysed in terms of successful detumescence and preservation of erectile function.


RESULTS
Detumescence was obtained and erectile function was preserved in almost 80% of cases, with conservative treatment alone. ICI (83%) and cooling (78%) were more effective as first-line treatment than puncture (57%). The delay to treatment was a more important parameter than the aetiology. Cooling was no longer effective after the 8th hour, puncture was no longer effective after the 9th hour and ICI was no longer effective after the 34th hour. Failures of conservative treatment and erectile sequelae were only observed in cases of priapism treated after the 24th hour.


CONCLUSIONS
The 3 methods have a similar degree of efficacy, provided they are performed early. Their indication depends on : 1) the duration of priapism, 2) the presence or absence of cavernosal anoxia. Schematically (and in parallel with aetiological treatment when possible) : a) in the case of painless priapism < 12 hours, cooling can be tried first, b) in the case of failure or painless priapism > 12, but < 24 hours, ICI of alpha-adrenergic agonists associated with puncture is indicated (except in the case of contraindications to ICI), c) in the case of painful priapism or > 24 hours, puncture must be the first treatment. In the case of failure, cavernosal blood gases should be performed to evaluate cavernosal anoxia and to guide management.
Bondil
P
P
Service d'Urologie-Andrologie, CHG de Chambéry, France.
Descottes
J L
JL
Salti
A
A
Sabbagh
R
R
Hamza
T
T
D000316:Adrenergic alpha-Agonists / Q000008:administration & dosage / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D003131:Combined Modality Therapy; D000075202:Contraindications; D017679:Cryotherapy; D006801:Humans; D000860:Hypoxia / Q000150:complications / Q000628:therapy; D007267:Injections; D008297:Male; D008875:Middle Aged; D010101:Oxygen Consumption; D010409:Penile Diseases / Q000150:complications / Q000628:therapy; D010410:Penile Erection; D010413:Penis / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology; D011317:Priapism / Q000188:drug therapy / Q000209:etiology / Q000628:therapy*; D011677:Punctures / Q000379:methods; D013997:Time Factors; D016896:Treatment Outcome
D000316:Adrenergic alpha-Agonists